OncoMatch/Clinical Trials/NCT07197671
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
Is NCT07197671 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies 90Y-NM600 for metastatic cancer.
Treatment: 90Y-NM600 — Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy (pembrolizumab, nivolumab, cemiplimab, dostarlimab)
Participants must be under treatment with one of the following FDA-approved standard-of-care anti-PD-1 or anti-PD-L1 therapies: Pembrolizumab (Keytruda; anti-PD-1 antibody), Nivolumab (Opdivo; anti-PD-1 antibody), Cemiplimab (Libtayo; anti-PD-1 antibody), Dostarlimab (Jemperli; anti-PD-1 antibody).
Must have received: anti-PD-L1 therapy (atezolizumab, avelumab, durvalumab)
Participants must be under treatment with one of the following FDA-approved standard-of-care anti-PD-1 or anti-PD-L1 therapies: Atezolizumab (Tecentriq, anti-PD-L1 antibody), Avelumab (Bavencio; anti-PD-L1 antibody), Durvalumab (Imfinzi; anti-PD-L1 antibody).
Cannot have received: systemic radioisotope therapy
Exception: except for benign thyroid disease
Participants that have had total body or hemibody irradiation, or have had prior systemic radioisotope therapy (except for benign thyroid disease)
Lab requirements
Blood counts
ANC ≥ 2000/μL; hemoglobin ≥ 8 g/dL; platelets ≥ 100,000/μL; without GM-CSF injection or transfusion in prior 7 days
Kidney function
Cockcroft-Gault calculated creatinine clearance >40 ml/min
Liver function
total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 3.0x ULN
adequate renal function as defined by Cockcroft-Gault calculated creatinine clearance >40 ml/min; adequate hepatic function as defined by: total bilirubin ≤ 1.5x ULN, AST and ALT ≤ 3.0x ULN; adequate hematologic function without GM-CSF injection or transfusion in the prior 7 days, as evidenced by: ANC ≥ 2000/μL, hemoglobin ≥ 8 g/dL, platelets ≥ 100,000/μL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UW Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07197671 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic radioisotope therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify